CONCLUSIONS
PD, injuries, SCIs
This study has demonstrated that KCL‐286 an orally available RARβ agonist, engages its receptor, and the safety, tolerability, PK and PD data support the use of up to 100 mg daily in fed conditions for future clinical studies in SCIs and other CNS injuries where axonal regeneration is required.